Abstract 17076: A Novel Polymer-Free Ciglitazone-Eluting Stent Inhibits Neointimal Proliferation Stronger than Sirolimus-Eluting Stents: An Experimental Study Using Optical Coherence Tomography in Rabbit Iliacal Arteries
Background: Drug-eluting stents (DES) are currently the best choice to reduce restenosis at long-term follow-up after percutaneous coronary interventions. Optical coherence tomography (OCT) is a high-resolution intravascular imaging technique that accurately distinguishes the various layers of the arterial wall, plaque composition and stent struts, allowing to precisely quantify the extent of neointimal proliferation .
Objective: To investigate ciglitazone, a peroxisome proliferator-activated receptor-gamma agonist as a novel stent coating.
Methods: Bare metal stents Yukon Choice 2.5/12 mm with microporous surface (BMS) were polymer-free coated with either sirolimus (SES) or ciglitazone (CES) at 225 mcg/cm. Twelve New Zealand White rabbits fed with high cholesterol western diet underwent implantation of different stents in both common iliacal arteries via the carotid artery. The animals were equally divided into 2 groups: BMS vs. SES and BMS vs. CES. After 90 days of dual antiplatelet therapy stents were imaged in vivo using OCT. An algorithm of quantitative assessment of neointimal growth was implemented (Figure 1) and applied to different stent segments and adjacent vessel areas.
Results: Relative proliferation area (S_PA%), calculated as neointimal area within a stent segment in relation to the stent area was significantly smaller in CES, but not in SES as compared to BMS (Figure 2).
Conclusions: (1) The described OCT measurements enable quantification of stent proliferation in detail. (2) The novel polymer-free ciglitazone-coated stent proved significant anti-restenotic efficacy in this rabbit model and merits attention as a promising stent development.
- © 2010 by American Heart Association, Inc.